| Literature DB >> 1403022 |
M J Steiger1, N P Quinn, C D Marsden.
Abstract
Our 2-year experience in the therapeutic use of subcutaneous apomorphine has involved 25 patients with Parkinson's disease, 10 of whom continue to use it chronically. On the basis of this experience, we have formulated certain indications for its use, together with suggested approaches to modify patients' oral drug regimes so that apomorphine can best be deployed to improve their quality of life.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1403022 DOI： 10.1007/bf00812157
Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849